Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015;2015(Suppl 4):10.19070/2328-353X-SI04001.
doi: 10.19070/2328-353X-SI04001. Epub 2015 Sep 28.

Obesity, Diabetes and Cancer: A Mechanistic Perspective

V Cifarelli  1 , S D Hursting  2
Affiliations

Obesity, Diabetes and Cancer: A Mechanistic Perspective

V Cifarelli et al. Int J Diabetol Vasc Dis Res. 2015.

Abstract

Nearly 35% of adults and 20% of children in the United States are obese, defined as having a body mass index (BMI) ≥ 30 kg/m2. Obesity is an established risk factor for many cancers, and obesity-associated metabolic perturbations often manifest in Type 2 diabetes mellitus and/or the metabolic syndrome. As part of the growth-promoting, proinflammatory microenvironment of the obese and/or diabetic state, crosstalk between macrophages, adipocytes, and epithelial cells occurs via metabolically-regulated hormones, cytokines, and other mediators to enhance cancer risk and/or progression. This review synthesizes the evidence on key biological mechanisms underlying the associations between obesity, diabetes and cancer, with particular emphasis on enhancements in growth factor signaling, inflammation, and vascular integrity processes. These interrelated pathways represent mechanistic targets for disrupting the obesity-diabetes-cancer link, and several diabetes drugs, such as metformin and rosiglitazone, are being intensely studied for repurposing as cancer chemopreventive agents.

Keywords: Cancer; Diabetes; Metformin; Obesity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Obesity, metabolic syndrome and cancer: overview of mechanisms. An arrow preceding text denotes a directional effect (eg, activity or concentration). Abbreviations: IGF-1, insulin-like growth factor-1; PAI 1, plasminogen activator inhibitor 1; tPA, tissue-type plasminogen activator; uPA, urokinase-type plasminogen activator; VEGF, vascular endothelial growth factor
See this image and copyright information in PMC

References

    1. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. JAMA. 2010;303(3):235–241. - PubMed
    1. Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race, and ethnicity, and body mass index: United States, 2003–2006. Natl Health Stat Report. 2009;(13):1–7. - PubMed
    1. Hursting SD, Berger NA. Energy balance, host-related factors, and cancer progression. J Clin Oncol. 2010;28(26):4058–4065. - PMC - PubMed
    1. Carter JC, Church FC. Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-gamma and plasminogen activator inhibitor-1. PPAR Res. 2009;2009:345320. - PMC - PubMed
    1. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol. 2006;26(5):968–976. - PubMed

LinkOut - more resources